Investigational new treatments for Clostridium difficile infection

Drug Discovery Today

Volumn 20, Issue 5, 2015, Pages 602-608

  Ivarsson, Mattias E ^a   Leroux, Jean Christophe ^a   Castagner, Bastien ^b  

^a ETH ZURICH   (Switzerland)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; NEW DRUG;

ANIMAL; CHEMISTRY; CLOSTRIDIUM INFECTIONS; DRUG DEVELOPMENT; DRUG EFFECTS; HOST PATHOGEN INTERACTION; HUMAN; MICROBIOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 84939574142     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.12.003     Document Type: Review

References (68)

1. A.F. Peery Burden of gastrointestinal disease in the United States: 2012 update Gastroenterology 143 2012 1179 1187
2. P.N. Wiegand Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection J. Hosp. Infect. 81 2012 1 14
3. A.N. Ananthakrishnan Clostridium difficile infection: epidemiology, risk factors and management Nat. Rev. Gastroenterol. Hepatol. 8 2011 17 26
4. M.P. Bauer Clostridium difficile infection in Europe: a hospital-based survey Lancet 377 2011 63 73
5. A.S. Chitnis Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011 JAMA Intern. Med. 173 2013 1359 1367
6. S.T. Cartman The emergence of hypervirulence in Clostridium difficile Int. J. Med. Microbiol. 300 2010 387 395
7. M. He Emergence and global spread of epidemic healthcare-associated Clostridium difficile Nat. Genet. 45 2012 109 113
8. K.E. Burke, and J.T. Lamont Clostridium difficile infection: a worldwide disease Gut Liver 8 2014 1 6
9. C.-A.D. Burnham, and K.C. Carroll Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories Clin. Microbiol. Rev. 26 2013 604 630
10. A.M. Jones Clostridium difficile: a European perspective J. Infect. 66 2013 115 128
11. I.A. Tickler Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013 Antimicrob. Agents Chemother. 58 2014 4214 4218
12. T. Jank, and K. Aktories Structure and mode of action of clostridial glucosylating toxins: the ABCD model Trends Microbiol. 16 2008 222 229
13. S.H. Cohen Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) Infect. Control Hosp. Epidemiol. 31 2010 431 455
14. D.G. Teasley Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis Lancet 2 1983 1043 1046
15. S.B. Debast European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection Clin. Microbiol. Infect. 20 Suppl 2 2014 1 26
16. C.M. Surawicz Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections Am. J. Gastroenterol. 108 2013 478 498 quiz 499
17. G.L. Kedderis Covalent interaction of 5-nitroimidazoles with DNA and protein in vitro: mechanism of reductive activation Chem. Res. Toxicol. 2 1989 146 149
18. P.E. Reynolds Structure, biochemistry and mechanism of action of glycopeptide antibiotics Eur. J. Clin. Microbiol. Infect. Dis. 8 1989 943 950
19. S. Löfmark Metronidazole is still the drug of choice for treatment of anaerobic infections Clin. Infect. Dis. 50 Suppl 1 2010 16 23
20. K.Z. Vardakas Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence Int. J. Antimicrob. Agents 40 2012 1 8
21. J. Freeman Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model J. Antimicrob. Chemother. 60 2007 83 91
22. W.N. Al-Nassir Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease Antimicrob. Agents Chemother. 52 2008 2403 2406
23. J.W. Lancaster, and S.J. Matthews Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections Clin. Ther. 34 2012 1 13
24. T.J. Louie OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection Antimicrob. Agents Chemother. 53 2009 261 263
25. G.W. Tannock A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin Microbiology 156 2010 3354 3359
26. T.J. Louie Fidaxomicin versus vancomycin for Clostridium difficile infection N. Engl. J. Med. 364 2011 422 431
27. G.G. Konijeti Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis Clin. Infect. Dis. 58 2014 1507 1514
28. M. Wagner Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada Can. J. Infect. Dis. Med. Microbiol. 25 2014 87 94
29. S.M. Bartsch Is fidaxomicin worth the cost? An economic analysis Clin. Infect. Dis. 57 2013 555 561
30. H.H. Locher Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections Antimicrob. Agents Chemother. 58 2014 901 908
31. C.T.M. Mascio In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile Antimicrob. Agents Chemother. 56 2012 5023 5030
32. C.H. Chilton In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection J. Antimicrob. Chemother. 69 2014 697 705
33. C.H. Chilton Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection J. Antimicrob. Chemother. 69 2014 2426 2433
34. R. Vickers SMT 19969 for Clostridium difficile infection (CDI): comparative efficacy compared to fidaxomicin and vancomycin in the hamster model of CDI ECCMID Barcelona, Spain 2014
35. J.Y. Chang Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea J. Infect. Dis. 197 2008 435 438
36. I. Youngster Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study Clin. Infect. Dis. 58 2014 1515 1522
37. L.J. Brandt Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection Am. J. Gastroenterol. 107 2012 1079 1087
38. B. Olle Medicines from microbiota Nat. Biotechnol. 31 2013 309 315
39. E. Van Nood Duodenal infusion of donor feces for recurrent Clostridium difficile N. Engl. J. Med. 368 2013 407 415
40. M.B. Smith Policy: how to regulate faecal transplants Nature 506 2014 290 291
41. M. Ratner Fecal transplantation poses dilemma for FDA Nat. Biotechnol. 32 2014 401 402
42. R. Blumberg, and F. Powrie Microbiota, disease, and back to health: a metastable journey Sci. Transl. Med. 4 2012 137rv7
43. L. Dethlefsen The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing PLoS Biol. 6 2008 e280
44. M. Beausoleil Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial Can. J. Gastroenterol. 21 2007 732 736
45. K. Atarashi Induction of colonic regulatory T cells by indigenous Clostridium species Science 331 2011 337 341
46. M. Miezeiewski An in vitro culture model to study the dynamics of colonic microbiota in Syrian golden hamsters and their susceptibility to infection with Clostridium difficile ISME J. 2014 10.1038/ismej.2014.127
47. C. Darkoh Bile salt inhibition of host cell damage by Clostridium difficile toxins PLOS ONE 8 2013 e79631
48. A. Howerton A new strategy for the prevention of Clostridium difficile infection J. Infect. Dis. 207 2013 1498 1504
49. M.M. Merrigan New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration Int. J. Antimicrob. Agents 33 Suppl 1 2009 46 50
50. J.K. Shim Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea Lancet 351 1998 633 636
51. M.S.M. Brouwer Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers Nat. Commun. 4 2013 2601
52. K.R. Hargreaves, and M.R.J. Clokie Clostridium difficile phages: still difficult? Front. Microbiol. 5 2014 184
53. E. Pennisi The CRISPR craze Science 341 2013 833 836
54. F. Winau, and R. Winau Emil von Behring and serum therapy Microbes Infect. 4 2002 185 188
55. J. Steele Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models J. Infect. Dis. 205 2012 384 391
56. O.R. Cohen Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model PLOS ONE 9 2014 e111075
57. Z. Zhang Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection Infect. Immun. 2014 10.1128/IAI.02550-14
58. N.L. Davies A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model Clin. Vaccine Immunol. 20 2013 377 390
59. A. Roberts Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection Infect. Immun. 80 2012 875 882
60. I. Lowy Treatment with monoclonal antibodies against Clostridium difficile toxins N. Engl. J. Med. 362 2010 197 205
61. G. Foglia Clostridium difficile: development of a novel candidate vaccine Vaccine 30 2012 4307 4309
62. L. Kyne Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A N. Engl. J. Med. 342 2000 390 397
63. L. Kyne Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea Lancet 357 2001 189 193
64. D. Boraschi The gracefully aging immune system Sci. Transl. Med. 5 2013 185ps8
65. P. Permpoonpattana Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B Infect. Immun. 79 2011 2295 2302
66. A. Ducher DAV132, developed to prevent side effects of antibiotics in the gut flora: results of a pilot cross-over study in healthy volunteers ECCMID Barcelona, Spain 2014
67. C. Miossec DAV131, an oral adsorbent-based product, exerts a dose-dependent protection of hamsters against moxifloxacin-induced Clostridium difficile lethal infection ECCMID Barcelona, Spain 2014
68. K. Weiss Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer Int. J. Antimicrob. Agents 33 2009 4 7